JJDS
Lv31
220 积分
2023-01-12 加入
-
Living in LALA land? Forty years of attenuating Fc effector functions
2小时前
已完结
-
Identification of Atypical Rhodococcus -Like Clinical Isolates as Dietzia spp. by 16S rRNA Gene Sequencing
4个月前
已完结
-
Safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of subcutaneous and intravenous ALXN1720 in healthy volunteers: a phase 1, randomized, double-blind, placebocontrolled, single and multiple ascending dose study (P1-5.016)
8个月前
已关闭
-
Characterization of the bispecific VHH antibody gefurulimab (ALXN1720) targeting complement component 5, and designed for low volume subcutaneous administration
8个月前
已完结
-
Advances in antibody phage display technology
9个月前
已完结
-
Isolation of Antigen-Specific VHH Single-Domain Antibodies by Combining Animal Immunization with Yeast Surface Display
9个月前
已完结
-
An alpaca single-domain antibody (VHH) phage display library constructed by CDR shuffling provided high-affinity VHHs against desired protein antigens
9个月前
已完结
-
Effects on weight loss and glycemic control with SAR441255, a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonist
10个月前
已完结
-
LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept
10个月前
已完结
-
Tirzepatide: A novel, first-in-class, dual GIP/GLP-1 receptor agonist
10个月前
已完结